返回 
加入收藏
两种中等强度他汀类药物方案治疗高脂血症的成本-效果分析
x
请在关注微信后，向客服人员索取文件
| 篇名： | 两种中等强度他汀类药物方案治疗高脂血症的成本-效果分析 |
| TITLE： | |
| 摘要： | 目的：探讨10 mg/d瑞舒伐他汀和20 mg/d阿托伐他汀治疗高脂血症（HLP）的有效性和经济性。方法：回顾性收集2015年3月－2016年2月天门市第一人民医院门诊收治的180例确诊为HLP的患者资料，根据治疗方案不同分为A、B组，各90例。A组患者给予阿托伐他汀钙片20 mg，qd；B组患者给予瑞舒伐他汀钙片10 mg，qd。两组患者疗程均为8周。比较两组患者治疗前后的血脂指标水平和治疗后的降脂疗效、血脂达标率及不良反应发生情况，并运用成本-效果分析法进行经济学评价。结果：治疗前，两组患者的血脂指标水平比较，差异均无统计学意义（P＞0.05）。治疗后，两组患者的总胆固醇和低密度脂蛋白胆固醇水平均明显低于治疗前，且B组水平明显低于A组，差异均有统计学意义（P＜0.05）；B组患者的降脂总有效率（97.78％）显著高于A组（86.67％），血脂达标率（66.67％）也显著高于A组（51.11％），差异均有统计学意义 （P＜0.05）。两组患者不良反应发生率比较，差异无统计学意义（P＞0.05）。A组和B组方案的成本分别为488.32、436.24元，成本-效果比分别为5.63、4.46，增量成本-效果比为－4.69，B组方案更具有成本-效果优势。敏感度分析支持成本-效果分析结果。结论：从短期疗效上分析，10 mg/d瑞舒伐他汀方案较20 mg/d阿托伐他汀方案的降脂效果更好，更具有成本-效果优势，且二者安全性相当。 |
| ABSTRACT： | OBJECTIVE： To investigate the effectiveness and economics of 10 mg/d rosuvastatin and 20 mg/d atorvastatin in the treatment of hyperlipidemia （HLP）. METHODS： The information of 180 HLP patients selected from Tianmen Municipal First People’s Hospital during Mar. 2015-Feb. 2016 were divided into group A and B according to medication regimen， with 90 cases in each group. Group A was given Atorvastatin calcium tablet 20 mg， qd； group B was given Rosuvastatin calcium tablet 10 mg， qd. Treatment course of 2 groups lasted for 8 weeks. Blood lipid indexes before and after treatment， lipid-lowering efficacy， the rate of qualified blood lipid and the occurrence of ADR after treatment were compared between 2 groups. Cost-effectiveness analysis was adopted for economic evaluation. RESULTS： Before treatment， there was no statistical significance in the levels of blood lipid indexes between 2 groups （P＞0.05）. After treatment， TC and LDL-C levels of 2 groups were significantly lower than before treatment， and those of group B were significantly lower than those of group A， with statistical significance （P＜0.05）. Total response rate of lipid-lowering in group B （97.78％） was significantly higher than group A （86.67％）， and the rate of qualified blood lipid （66.67％） was also significantly higher than group A （51.11％）， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of ADR between 2 groups （P＞0.05）. The costs of group A and B were 488.32， 436.24 yuan， and cost-effectiveness ratios were 5.63， 4.46； incremental cost-effectiveness ratio was －4.69. The plan of group B had cost-effectiveness advantage. The results of cost-effectiveness analysis were supported by sensitivity analysis. CONCLUSIONS： In the view of short-term efficacy， 10 mg/d rosuvastatin plan is better than 20 mg/d atorvastatin plan in lowering lipid and has cost-effectiveness advantage， and both have similar safety. |
| 期刊： | 2017年第28卷第26期 |
| 作者： | 郭胜红，汪延安，孙文武，万书平，孙治华，杨广龙，朱丽华 |
| AUTHORS： | GUO Shenghong，WANG Yan’an，SUN Wenwu，WAN Shuping，SUN Zhihua，YANG Guanglong，ZHU Lihua |
| 关键字： | 阿托伐他汀；瑞舒伐他汀；高脂血症；成本-效果分析；药物经济学；中等强度他汀类药物方案 |
| KEYWORDS： | Atorvastatin； Rosuvastatin； Hyperlipoidemia； Cost-effectiveness analysis； Pharmacoeconomics； Moderate intensity statins plan |
| 阅读数： | 250 次 |
| 本月下载数： | 10 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
